Survival of colorectal cancer has improved three fold within the last three decades leaving the majority of patients treated for colorectal cancer at risk for late adverse effects. Recent population based studies have shown that approximately 50% of patients suffer from late adverse effects with significant impact on quality of life. Following treatment of rectal cancer both surgery and neoadjuvant chemoirradiation may comprise not only bowel function but also urinary and sexual function, and these late adverse effects often coexist. Following colonic cancer, it appears that diarrhoea is the main problem following right-sided hemicolectomy and obstructed defecation is the main problem in left-sided hemicolectomy. Further studies are required to expand our knowledge on pathophysiology, how patients who require treatment can be identified, the optimal treatment strategy, and the clinical outcome.
There are several ways of detecting the late adverse effects of colorectal cancer treatment. This Research Topic aims to generate a discussion of how to identify and improve the late adverse effects following the treatment for colorectal cancer patients. This includes patient reported outcomes, validated questionnaires, large prospective cohort studies. Pathophysiology studies could develop a further understanding in which changes in physiology lead to bowel dysfunction, urinary dysfunction, sexual dysfunction, and chronic pain. Treatment strategies based on a well defined cohort, develop simple and cost effective strategies based on improvement in function and quality of life.
This Research Topic welcomes Original Research Articles and Review Articles. Themes of interest include:
-Bowel dysfunction
-Sexual dysfunction
-Urinary dysfunction
-Ostomy
-Chronic pain
-Follow-up strategy and quality of life
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Survival of colorectal cancer has improved three fold within the last three decades leaving the majority of patients treated for colorectal cancer at risk for late adverse effects. Recent population based studies have shown that approximately 50% of patients suffer from late adverse effects with significant impact on quality of life. Following treatment of rectal cancer both surgery and neoadjuvant chemoirradiation may comprise not only bowel function but also urinary and sexual function, and these late adverse effects often coexist. Following colonic cancer, it appears that diarrhoea is the main problem following right-sided hemicolectomy and obstructed defecation is the main problem in left-sided hemicolectomy. Further studies are required to expand our knowledge on pathophysiology, how patients who require treatment can be identified, the optimal treatment strategy, and the clinical outcome.
There are several ways of detecting the late adverse effects of colorectal cancer treatment. This Research Topic aims to generate a discussion of how to identify and improve the late adverse effects following the treatment for colorectal cancer patients. This includes patient reported outcomes, validated questionnaires, large prospective cohort studies. Pathophysiology studies could develop a further understanding in which changes in physiology lead to bowel dysfunction, urinary dysfunction, sexual dysfunction, and chronic pain. Treatment strategies based on a well defined cohort, develop simple and cost effective strategies based on improvement in function and quality of life.
This Research Topic welcomes Original Research Articles and Review Articles. Themes of interest include:
-Bowel dysfunction
-Sexual dysfunction
-Urinary dysfunction
-Ostomy
-Chronic pain
-Follow-up strategy and quality of life
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
